Key Points
Analysts expect $0.2184 EPS and $4.64B revenue on May 15.
Alfresa missed estimates three of last four quarters, suggesting downside risk.
Thin 1.1% net margin and 7.1% gross margin limit earnings upside potential.
Meyka AI B grade reflects fair valuation but limited growth catalysts in competitive pharma distribution.
Alfresa Holdings Corporation, a major Japanese pharmaceutical and medical device distributor, reports earnings on May 15, 2026. Analysts expect earnings per share of $0.2184 and revenue of $4.64 billion. The ARHCF stock trades at $11.87 with a market cap of $2.16 billion. The company operates across ethical pharmaceuticals, over-the-counter products, and medical equipment distribution. Recent quarters show mixed performance, with earnings volatility and revenue fluctuations. Investors will focus on gross margins, wholesale volumes, and guidance for the healthcare distribution sector.
Earnings Estimates and Historical Performance
Alfresa’s earnings preview shows analysts expecting $0.2184 EPS and $4.64 billion in revenue for the upcoming quarter. This represents a significant decline from the prior quarter’s $0.718 EPS and $5.32 billion revenue reported in February 2026.
Recent Earnings Trend
The company has delivered mixed results over the last four quarters. In February 2026, Alfresa beat EPS estimates of $0.4176 with actual earnings of $0.718, a 72% beat. Revenue also exceeded expectations at $5.32 billion versus $4.92 billion estimated. However, the August 2025 quarter showed weakness, with EPS of $0.191 missing the $0.2574 estimate by 26%. Revenue came in at $5.26 billion, slightly above the $5.14 billion estimate. The May 2025 quarter saw EPS of $0.06258, missing the $0.1951 estimate by 68%, indicating significant earnings pressure.
What the Estimates Mean
The current $0.2184 EPS estimate sits between recent quarters’ performance. This suggests analysts expect stabilization after the volatile results. The $4.64 billion revenue estimate is below the February quarter but above the May 2025 level. The company’s pharmaceutical distribution business faces pricing pressure and volume challenges in competitive markets.
Beat or Miss Prediction Based on Historical Patterns
Alfresa’s earnings history reveals a pattern of significant volatility, making predictions challenging but informative for investors.
Beat Probability Assessment
The company has beaten EPS estimates once in the last four quarters (February 2026 with a 72% beat). It missed estimates three times, with the May 2025 quarter showing a dramatic 68% miss. This suggests a higher probability of missing current estimates. Revenue performance is more consistent, with two beats and two near-misses. The current $0.2184 EPS estimate appears conservative relative to the February beat, but aggressive compared to recent weakness.
Key Risk Factors
Margin compression remains a critical concern. The company’s net profit margin sits at 1.1%, indicating thin profitability in pharmaceutical distribution. Operating margins of 1.2% leave little room for cost overruns. If wholesale volumes decline or pricing pressure intensifies, Alfresa could miss estimates. Conversely, strong demand from hospitals and clinics could drive an upside surprise. The company’s ability to manage inventory efficiently will be crucial, as inventory turnover of 14.6x shows rapid stock movement.
Key Metrics Investors Should Watch
Several financial metrics will determine whether Alfresa meets or beats expectations in the May 15 earnings report.
Gross Margin Trends
Gross profit margin of 7.1% is critical for pharmaceutical distributors. Any compression below this level signals pricing pressure or unfavorable product mix shifts. Investors should monitor whether the company maintained margins despite competitive pressures in Japan’s healthcare market. A 50-basis-point decline would significantly impact bottom-line earnings.
Operating Efficiency
Operating cash flow and working capital management matter significantly. The company’s current ratio of 1.2x indicates adequate liquidity, but days sales outstanding of 89 days shows extended payment terms. If receivables collection slows, cash flow could deteriorate. The company’s inventory-to-sales ratio of 25 days is healthy, suggesting efficient stock management.
Dividend Sustainability
Alfresa maintains a 3.7% dividend yield with annual dividends of $70.02 per share. The payout ratio appears sustainable given the current earnings level. However, if earnings decline further, dividend coverage could become strained. Investors should watch for any guidance changes regarding shareholder returns.
What to Watch: Sector Trends and Meyka AI Grade
The pharmaceutical distribution sector faces structural headwinds that will influence Alfresa’s performance and outlook.
Healthcare Distribution Sector Dynamics
Japan’s aging population drives steady demand for pharmaceuticals and medical devices. However, government price controls and consolidation among hospital buyers create margin pressure. Generic drug penetration continues rising, which typically compresses distributor margins. Alfresa’s diversification into over-the-counter products and medical equipment provides some offset, but the core wholesale business remains under pressure.
Meyka AI Grade Analysis
Meyka AI rates ARHCF with a grade of B, reflecting moderate fundamentals and mixed growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B grade suggests the stock is fairly valued but faces headwinds. The company’s price-to-earnings ratio of 10.1x is reasonable for a mature healthcare distributor, while the price-to-book ratio of 0.69x indicates potential value. However, declining earnings momentum and thin margins limit upside potential. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
Alfresa Holdings reports earnings on May 15 with expected EPS of $0.2184 and $4.64 billion revenue. The company has missed estimates in three of the last four quarters, indicating downside risk. Thin margins (1.1% net, 7.1% gross) leave minimal room for error. Investors should monitor margin trends, wholesale volumes, and working capital. The Meyka AI B grade suggests fair valuation with limited growth catalysts. Success requires maintaining pricing discipline and cost control in Japan’s competitive pharmaceutical distribution market.
FAQs
What EPS and revenue are analysts expecting from Alfresa’s May 15 earnings?
Analysts expect $0.2184 EPS and $4.64 billion revenue, down from February 2026’s $0.718 EPS and $5.32 billion. The decline reflects seasonal patterns and market conditions in pharmaceutical distribution.
Has Alfresa beaten or missed earnings estimates recently?
Alfresa shows mixed results: beat EPS by 72% in February 2026 but missed three of four recent quarters, including a 68% miss in May 2025. This volatility suggests elevated risk for current estimates.
What are the main risks to Alfresa’s earnings this quarter?
Key risks include margin compression from pricing pressure, declining wholesale volumes, and inventory challenges. The 1.1% net margin leaves little room for cost overruns. Healthcare consolidation and generic drug penetration also pressure profitability.
What does Meyka AI’s B grade mean for Alfresa stock?
The B grade reflects fair valuation with limited growth catalysts. The stock appears reasonably priced at 10.1x earnings but faces headwinds from thin margins and declining earnings momentum.
Should investors be concerned about Alfresa’s dividend sustainability?
The 3.7% dividend yield appears sustainable at current earnings, with $70.02 annual dividends. However, further earnings declines could strain coverage. Monitor earnings trends before the next distribution.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)